AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes
First participants with Type 2 diabetes dosed in multiple ascending dose (MAD) study evaluating AdipoPharma’s first-in-class insulin sensitizer Advancement follows successful completion of the single ascending dose (SAD) phase, where PATAS was well tolerated with no serious adverse events STRASBOURG,